Spectrum Pharmaceuticals, Inc.

University of Illinois

Hanmi Pharmaceutical Co., Ltd.

Acrotech Biopharma Inc.

Guru Reddy

Luigi Lenaz

Anil Gulati

Bastiaan Nuijen

Dorla Mirejovsky

Ernie Pfadenhauer

Jos H Beijnen

Steffan Nawrocki

Jennifer Carew

Hee Cheol Kim

Jong Ouk Baek

Kweehyun Suh

Steffan T Nawrocki

This patent document relates to the crystalline forms of a quinazoline compound and the hydrochloride salts thereof. More particularly, this patent document relates to a preparation method of the crystalline forms of 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one and its hydrochloride salts.

Crystalline forms of a quinazoline compound and its hydrochloride salts

The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of belinostat and pralatrexate, wherein said therapeutically effective amount results in a synergistic antiproliferative effect on cancer cell growth.

Combination therapy using belinostat and pralatrexate to treat lymphoma

Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

Bladder cancer treatment and methods

The present specification provides compositions comprising a thioxanthone-based autophagy inhibitor and/or a cancer therapeutic autophagy inducing compound, pharmaceutical kits comprising these compositions, and methods of treating cancer using such compounds, compositions and kits. Additionally, the present specification provides methods of treating cancer using a thioxanthone-based autophagy inhibitor and a radiotherapy.

Thioxanthone-based autophagy inhibitor therapies to treat cancer

Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ETagonist IRL1620.

Sensitization of tumor cells to radiation therapy through administration of endothelin agonists

Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ET) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.

Methods, compositions and articles of manufacture for contributing to the treatment of cancers

Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ET) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).

Growing community of inventors

Irvine, CA, United States of America

Guru Reddy